Published in J Cell Biochem on January 01, 2003
1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene (p,p'-DDE) disrupts the estrogen-androgen balance regulating the growth of hormone-dependent breast cancer cells. Breast Cancer Res (2008) 0.89
Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression. Neoplasia (2015) 0.85
Blockade of Autocrine TGF-β Signaling Inhibits Stem Cell Phenotype, Survival, and Metastasis of Murine Breast Cancer Cells. J Stem Cell Res Ther (2012) 0.84
Bergapten induces ER depletion in breast cancer cells through SMAD4-mediated ubiquitination. Breast Cancer Res Treat (2012) 0.81
Human phosphatidylethanolamine-binding protein 4 promotes transactivation of estrogen receptor alpha (ERalpha) in human cancer cells by inhibiting proteasome-dependent ERalpha degradation via association with Src. J Biol Chem (2010) 0.79
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis. Multidiscip Respir Med (2011) 0.78
BMP4 Cross-talks With Estrogen/ERα Signaling to Regulate Adiposity and Glucose Metabolism in Females. EBioMedicine (2016) 0.75
Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals. Breast Cancer Res Treat (2016) 0.75
Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res (1990) 9.85
Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell (2000) 6.69
Mechanisms of estrogen action. Physiol Rev (2001) 5.97
Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev (1996) 5.17
A review of the epidemiology of human breast cancer. Epidemiol Rev (1979) 4.04
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69
Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem (2000) 3.12
Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci U S A (1997) 2.97
36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res (1991) 2.96
Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst (1994) 2.93
Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci U S A (1999) 2.81
Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science (1987) 2.69
Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science (1993) 2.35
TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol (2001) 2.28
Estrogen receptor interaction with co-activators and co-repressors. Steroids (2000) 1.91
Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev (2001) 1.91
Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A (1999) 1.87
Molecular and cell biology of TGF-beta. Miner Electrolyte Metab (1998) 1.86
Transforming growth factor-beta: a general review. Eur Cytokine Netw (1996) 1.85
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J (1999) 1.54
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol (1991) 1.43
Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem (1999) 1.42
Effect of estradiol on human breast cancer cells in culture. Cancer Res (1983) 1.41
Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep (2001) 1.37
A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer (1997) 1.26
Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene (1999) 1.21
Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta-dependent transcription. J Biol Chem (2001) 1.17
Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta (1979) 1.16
Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res (1997) 1.11
Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem (1998) 1.10
Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia (1999) 1.06
Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology (2002) 1.05
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. Biochem Biophys Res Commun (1999) 1.04
Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer (1986) 0.94
Regulation of estrogen receptor alpha function in breast cancer. Crit Rev Oncog (1997) 0.89
The smad proteins and TGFbeta signalling: uncovering a pathway critical in cancer. Pathology (2001) 0.85
Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol (2000) 0.84
Three distinct roles for TGF-beta during intercellular induction of apoptosis: a review. Anticancer Res (1999) 0.81
Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells. Gene Expr (2001) 0.81
Deregulated expression of cyclin D1 overrides antimitogenic signals. Oncogene (2000) 0.80
Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Ann Surg (1998) 0.78
Growth inhibitors for mammary epithelial cells. Prog Mol Subcell Biol (1998) 0.77
The role of transforming growth factor-beta in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology (1997) 0.77
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab (2005) 1.56
Reconsidering the length of program accreditation. Am J Pharm Educ (2011) 1.44
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem (2006) 1.19
Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis (2003) 1.16
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther (2008) 1.15
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol (2005) 1.13
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab (2003) 1.12
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol (2006) 1.12
The final catalytic step of cytochrome p450 aromatase: a density functional theory study. J Am Chem Soc (2005) 1.08
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol (2002) 1.05
Are we producing innovators and leaders or change resisters and followers? Am J Pharm Educ (2012) 1.00
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem (2006) 0.99
Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm (2010) 0.97
Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J Comb Chem (2008) 0.93
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem (2007) 0.90
SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm (2011) 0.88
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod (2006) 0.88
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod (2008) 0.87
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem (2008) 0.84
Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol (2002) 0.84
Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine (2012) 0.83
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett (2003) 0.83
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer (2011) 0.82
Natural products as aromatase inhibitors. Anticancer Agents Med Chem (2008) 0.82
Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem (2005) 0.82
Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int J Pharm (2012) 0.81
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg Med Chem (2005) 0.81
Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer. Anticancer Res (2010) 0.81
Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem (2004) 0.80
Role of the azinomycin naphthoate and central amide in sequence-dependent DNA alkylation and cytotoxicity of epoxide-bearing substructures. Org Lett (2002) 0.80
Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol (2007) 0.79
Maintaining pharmacy education's research focus as the academy expands. Am J Pharm Educ (2012) 0.78
Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett (2009) 0.77
Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Res (2008) 0.76
Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anticancer Agents Med Chem (2016) 0.75
Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells. Anticancer Res (2012) 0.75
4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J Steroid Biochem Mol Biol (2007) 0.75